NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Ltd. Kck Sells 6,900 Shares of Stock

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 6,900 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $6.57, for a total value of $45,333.00. Following the completion of the transaction, the insider now owns 5,510,957 shares in the company, valued at $36,206,987.49. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The shares were sold at an average price of $6.54, for a total value of $26,362.74.
• On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The stock was sold at an average price of $6.35, for a total value of $16,332.20.
• On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The shares were sold at an average price of $6.10, for a total transaction of $19,050.30.
• On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The shares were sold at an average price of $6.66, for a total transaction of $32,700.60.
• On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The stock was sold at an average price of $6.97, for a total value of $23,126.46.

NeuroPace Trading Up 1.3 %

NASDAQ:NPCE opened at $6.47 on Friday. The stock has a 50-day simple moving average of $7.05 and a 200-day simple moving average of $8.41. The stock has a market cap of $186.13 million, a P/E ratio of -5.44 and a beta of 1.78. NeuroPace, Inc. has a 1 year low of $5.73 and a 1 year high of $18.15. The company has a debt-to-equity ratio of 5.97, a quick ratio of 5.47 and a current ratio of 6.37.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.03. NeuroPace had a negative net margin of 41.63% and a negative return on equity of 195.26%. The company had revenue of $19.26 million during the quarter, compared to the consensus estimate of $18.30 million. During the same quarter in the prior year, the firm posted ($0.36) earnings per share. NeuroPace’s revenue for the quarter was up 16.6% on a year-over-year basis. As a group, analysts anticipate that NeuroPace, Inc. will post -1.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NeuroPace

Large investors have recently modified their holdings of the company. Rhumbline Advisers acquired a new stake in NeuroPace during the 2nd quarter worth $111,000. Financial Advocates Investment Management boosted its stake in shares of NeuroPace by 50.0% during the second quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock worth $113,000 after buying an additional 5,000 shares during the period. Hillsdale Investment Management Inc. purchased a new position in shares of NeuroPace during the first quarter worth about $155,000. XTX Topco Ltd increased its position in NeuroPace by 56.1% in the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after acquiring an additional 8,643 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in NeuroPace during the 2nd quarter valued at approximately $257,000. 78.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NPCE has been the topic of several research reports. Morgan Stanley decreased their target price on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 price target on shares of NeuroPace in a research report on Wednesday, August 14th. Finally, Wells Fargo & Company cut their price objective on NeuroPace from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.